VERAPAMIL HYDROCHLORIDE tablet, film coated, extended release

Ország: Egyesült Államok

Nyelv: angol

Forrás: NLM (National Library of Medicine)

Aktív összetevők:

VERAPAMIL HYDROCHLORIDE (UNII: V3888OEY5R) (VERAPAMIL - UNII:CJ0O37KU29)

Beszerezhető a:

Carilion Materials Management

INN (nemzetközi neve):

VERAPAMIL HYDROCHLORIDE

Összetétel:

VERAPAMIL HYDROCHLORIDE 180 mg

Az alkalmazás módja:

ORAL

Recept típusa:

PRESCRIPTION DRUG

Terápiás javallatok:

Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacolo

Termék összefoglaló:

Product: 68151-0693 NDC: 68151-0693-1 1 TABLET, FILM COATED, EXTENDED RELEASE in a BLISTER PACK

Engedélyezési státusz:

Abbreviated New Drug Application

Termékjellemzők

VERAPAMIL HYDROCHLORIDE- VERAPAMIL HYDROCHLORIDE TABLET, FILM COATED,
EXTENDED
RELEASE
CARILION MATERIALS MANAGEMENT
----------
DESCRIPTION
Verapamil hydrochloride extended-release tablets, USP are a calcium
ion influx inhibitor (slow-channel
blocker or calcium ion antagonist). Verapamil hydrochloride
extended-release tablets are available for
oral administration as blue, film-coated, oval, unscored tablets
debossed with MYLAN on one side of
the tablet and 244 on the other side containing 120 mg of verapamil
hydrochloride; as blue, film-coated,
oval tablets debossed with M to the left of the score and 312 to the
right of the score on one side of the
tablet and blank on the other side containing 180 mg of verapamil
hydrochloride; and as blue, film-
coated, modified capsule-shaped tablets debossed with M to the left of
the score and 411 to the right of
the score on one side of the tablet and blank on the other side
containing 240 mg of verapamil
hydrochloride. The tablets are designed for extended-release of the
drug in the gastrointestinal tract;
extended-release characteristics are not altered when the tablet is
divided in half.
The structural formula of verapamil hydrochloride is:
C
H N O • HCL M.W. = 4 91.06
(±)-5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
monohydrochloride
Verapamil hydrochloride, USP is an almost white, crystalline powder,
practically free of odor, with a
bitter taste. It is soluble in water, chloroform, and methanol.
Verapamil hydrochloride is not chemically
related to other cardioactive drugs.
Inactive ingredients include FD&C Blue No. 1 Aluminum Lake, magnesium
stearate, microcrystalline
cellulose, polyethylene glycol, polyvinyl alcohol, povidone, sodium
alginate, sodium lauryl sulfate,
talc, and titanium dioxide.
Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg meet _USP
Dissolution Test 1_.
Verapamil Hydrochloride Extended-Release Tablets USP, 180 mg and 240
mg meet _USP Dissolution_
_Test 3_.
CLINICAL PHARMACOLOGY
Verapamil hydr